StockNews.com announced that it would cover CVS Health in a research report distributed to investors on Thursday.
The report was titled “CVS Health Coverage.” The pharmacy operator’s stock was given a “buy” recommendation by the company, which the company issued.
You can locate the most recent quarterly earnings report for CVS Health, announced on February 8th, on the NYSE under the ticker CVS symbol.
This report was released in the United States.
The pharmacy proprietor reported earnings per share for the quarter of $1.99, which was $0.07 higher than the consensus estimate of $1.92.
In the case of CVS Health, the return on equity was 15.75 percent, and the company’s net margin was 1.29%.
The quarterly sales for the company came in at $83.85 billion, significantly higher than the $76.37 billion that the analysts had predicted they would be for the company.
The company reported a profit of $1.98 per share for the quarter, compared to the results it achieved during the same period the year before.
The results of the company’s most recent quarter showed a 9.5% increase in sales compared to the same quarter’s results from the year before. Researchers anticipate that CVS Health will generate earnings per share of $8.84 during the company’s current fiscal year.
Thursday began with a $75.40 opening price for the CVS stock on the NYSE. However, the current ratio is equal to 0.94, and the quick ratio is equal to 0.67.
The debt-to-equity ratio, the current ratio, and the quick ratio are all equal to 0.71.
In the previous year, CVS Health had prices ranging from as low as $74.52 to as high as $109.69.
The lowest price it ever reached was $74.52.
The moving average for the first 50 days of the company’s operations is $86.04, and the moving average for the first 200 days is $93.35.
The company’s market capitalization is currently sitting at $96.82 billion.
It has a price-to-earnings ratio of 24.17, a price-to-earnings-growth ratio of 1.19, and a beta of 0.65.
CVS has been the subject of investigation in several additional scientific studies in recent years.
In a research report that was released on November 25th, TheStreet upgraded the stock rating of CVS Health from “c-” to “b.” The rating had been previously held at “c+.” In a research note published on February 9th, Raymond James lowered their price objective on CVS Health shares from $115.00 to $110.00.
Despite this change, Raymond James has recommended that investors “outperform” the stock.
The analysts at Jefferies Financial Group upgraded their recommendation for purchasing CVS Health stock to “buy” and increased their price objective from $130.00 to $143. On February 9th, a research report that incorporated all of these amendments into its findings was distributed.
Morgan Stanley raised their price objective for CVS Health from $119.00 to $120.00 and upgraded the stock’s rating from “underweight” to “overweight” in a research report regarding the company that was published on Friday, January 13th.
The Royal Bank of Canada reaffirmed an “outperform” rating on shares of CVS Health and positioned them with a price objective of $115.00 in a research report made public on Thursday, February 9th.
There have been three research analysts who have recommended that their clients maintain their hold positions with the company, while there have been fourteen research analysts who have given the stock a buy rating.
The current consensus rating for CVS Health is “Moderate Buy,” and the price objective for the stock is set at $119.65, as indicated by the information that can be found on Bloomberg.com.
Recently, hedge funds have gone through the process of changing their stock holdings.
During the third quarter, Diversified Trust Company increased the proportion of CVS Health stock owned by one-hundredth of one percent.
After making an additional purchase of 145 shares during the relevant period, Diversified Trust Company now owns 14,899 shares of the drugstore operator’s stock, which have a combined value of $1,421,000.
These shares were acquired during the period in question.
In the third quarter, Carnegie Capital Asset Management LLC made a 28.9% purchase of additional CVS Health stock, bringing the total amount of the company’s CVS Health stock ownership to 100%. Carnegie Capital Asset Management LLC now has 55,867 shares of the drugstore operator’s stock, worth a combined $5,328,000 after the company purchased 12,527 shares during the relevant time period.
The amount of CVS Health common stock that Bond & Devick Financial Network INC owned as of the end of the third quarter was up 1.9% compared to the beginning of the quarter.
Bond & Devick Financial Network INC now has 10,820 shares of the drugstore operator’s stock, with a market value of $1,032,000.
This results from the company purchasing an additional 200 shares during the relevant period.
During the second quarter, Royal London Asset Management Ltd increased the amount of CVS Health stock owned by 1.3%, bringing the total amount of stock it owned to 2%. Royal London Asset Management Ltd now has a total holdings volume of 470,446 shares of the drugstore operator’s stock, valued at $43,601,000 after purchasing an additional 6,045 shares during the most recent quarter.
This brings the total value of their holdings to $43,601,000.
And finally, during the third quarter, Ritholtz Wealth Management accomplished an increase of 107.8 percent in the proportion of CVS Health stock it owns. Following acquiring an additional 13,813 shares during the most recent quarter, Ritholtz Wealth Management now holds 26,627 shares of the drugstore operator’s stock.
These 26,627 shares are currently valued at a combined total of $2,539,000.
Institutional investors and hedge funds collectively own 77.29 percent of the total number of shares issued by the company.
In addition to providing solutions for healthcare needs, CVS Health Corp.
Also provides medical services.
Pharmaceutical services, retail or long-term care, health care benefits, and corporate and other are the company’s four distinct business divisions that operate independently from one another.
The market for pharmacy services is primarily concerned with the research, development, and implementation of solutions for pharmaceutical benefit management.